Status:
COMPLETED
Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients
Lead Sponsor:
Michael Pfeilstöcker
Collaborating Sponsors:
Celgene Corporation
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
Brief Summary
A comparison of treated vs untreated patients with MDS with a sample size of approximately 8000 patients in 11 countries.
Detailed Description
Non-interventional multicentre retrospective study using chart reviews - study was submitted to the ethics committee of city of Vienna - due to the design of the study no specific approval necessary. ...
Eligibility Criteria
Inclusion
- MDS (all subtypes and risk groups) according to WHO or oligoblastic AML (RAEB-T according to FAB) patients untreated and treated during their chronic MDS phase
Exclusion
- None
Key Trial Info
Start Date :
August 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 21 2022
Estimated Enrollment :
9179 Patients enrolled
Trial Details
Trial ID
NCT04676945
Start Date
August 21 2020
End Date
November 21 2022
Last Update
November 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanusch Krankenhaus, 3.Medizinische Abteilung
Vienna, Austria, 1140